MedTrace Logo

Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors

NCT01415297 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-05-19

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and maximal tolerated dose of NKP-1339, a ruthenium containing compound administered intravenously on a weekly schedule, in patients with advanced solid tumors. The responses to treatment in this population will be evaluated. In addition, the PD and PK properties of the compound will be explored.

Conditions

Interventions

DRUG

NKP-1339

NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.

Sponsors & Collaborators

  • Niiki Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Daniel D. Von Hoff, MD · TGEN Clinical Research Services at Scottsdale Healthcare

  • Howard A. Burris, III, MD · The Sarah Cannon Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-05-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01415297 on ClinicalTrials.gov